Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals … – 7thSpace Interactive (press release)

Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals
7thSpace Interactive (press release)
Despite the availability of effective therapies, asthma remains a source of significant morbidity and use of health care resources. The central research question of the ACCURATE trial is whether maximal doses of (combination) therapy should be used for

View full post on asthma – Google News

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Condition:   Asthma
Interventions:   Drug: 50 mcg salmeterol HFA MDI;   Drug: placebo;   Drug: 5 mcg tiotropium Respimat®;   Drug: 2.5 mcg tiotropium Respimat®
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days